SCHEMBL9107031

SCHEMBL9107031

Cc1ccc(CC(C=O)c2cccc(Cl)c2)cc1C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.44
PNMT P11086 1/20 0.40
ADRB3 P13945 8/20 0.36
ADRB1 P08588 7/20 0.36
SLC2A1 P11166 2/20 0.36
CTSB P07858 1/20 0.36
ADRB2 P07550 3/20 0.35
PKM P14618 1/20 0.35
CNR1 P21554 1/20 0.35
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108230 0.83 CTSB (0.36) S1PR1CTSB
SCHEMBL27920366 0.83 PNMT (0.38) PNMTADRB3ADRB1SLC2A1CTSB
SCHEMBL9112140 0.81 CHRM2 (0.45)
SCHEMBL9909350 0.78 S1PR1 (0.43) S1PR1PNMTADRB3ADRB1SLC2A1
SCHEMBL9104383 0.77 S1PR1 (0.46) S1PR1PNMTADRB3ADRB1SLC2A1
SCHEMBL9101178 0.77 MEN1 (0.52) S1PR1ADRB3ADRB1CTSBADRB2
SCHEMBL27506218 0.76 ACP3 (0.40) PNMT
SCHEMBL16468984 0.75 S1PR1 (0.56) S1PR1PNMTADRB3ADRB1SLC2A1
SCHEMBL16468959 0.75 S1PR1 (0.56) S1PR1PNMTADRB3ADRB1SLC2A1
SCHEMBL16469218 0.75 S1PR1 (0.56) S1PR1PNMTADRB3ADRB1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993553-B2 Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2015-03-31 US disclosed
WO-2014078206-A1 ALLENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-05-22 WO disclosed
US-20140135293-A1 ALLENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-05-15 US disclosed
US-20130310359-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-11-21 US disclosed
EP-2646415-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS Allergan, Inc. (US) 2013-10-09 EP disclosed
US-8492561-B2 Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20120142662-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed
WO-2012074926-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310359-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR2, S1PR5 S1PR1 1/4885PNMT 2565/4885ADRB3 177/4885
US-20140135293-A1 ALLENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR2, S1PR3 S1PR1 1/4885PNMT 3379/4885ADRB3 198/4885
US-20120142662-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR2, S1PR5 S1PR1 1/4885PNMT 2565/4885ADRB3 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.